In higher-risk patients with atrial fibrillation (AF), treatment with non-vitamin K antagonist oral anticoagulants (NOACs) significantly reduced 2-year mortality compared to those treated with vitamin K antagonists (VKAs), according to findings from a new analysis of a large, multinational, prospective AF registry. 

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is a worldwide observational program that includes 57,262 patients newly diagnosed with newly diagnosed nonvalvular AF and with ≥1 risk factor for stroke. The new analysis – presented at the ESC Congress 2018 – included 19,134 of these patients and showed that there were 19% fewer deaths in patients started on NOACs vs VKAs at the time of AF diagnosis (adjusted hazard ratio [HR] 0.81, 95% CI, 0.71, 0.92; <.001).

Additional data of higher-risk patients (CHA2DS2-VASc score ≥2) in the GARFIELD-AF registry (N=26,742) showed there were 17% fewer deaths (HR 0.83, 95% CI, 0.75, 0.93; <.001) and 27% fewer strokes/systemic emboli (HR 0.73, 95% CI, 0.59, 0.90; =.003) when treated with anticoagulants (AC) vs those receiving no AC therapy. 

Continue Reading

Among patients with new onset AF and no prior antiplatelet (AP) or AC use, treatment with both AC+AP had a higher risk of major bleeding (HR 1.45, 95% CI, 0.94, 2.23) and all-cause mortality (HR 1.31, 95% CI, 1.05, 1.62) without a reduction in stroke (HR 1.60, 95% CI, 1.08, 2.35), when compared with AC alone.

Related Articles

For more information visit

This article originally appeared on MPR